The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature

The Status Quo of Pharmacogenomics of Tyrosine Kinase Inhibitors in Precision Oncology: A Bibliometric Analysis of the Literature

Precision oncology and pharmacogenomics (PGx) intersect in their overarching goal to institute the right treatment for the right patient. However, the translation of these innovations into clinical practice is still lagging behind. Therefore, this study aimed to analyze the current state of research...

Full description

Bibliographic Details
Main Authors: Abdallah Alzoubi, Hassan Shirazi, Ahmad Alrawashdeh, Arwa M. AL-Dekah, Nadia Ibraheem, Khalid A. Kheirallah
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Pharmaceutics
Subjects:
pharmacogenomics
pharmacogenetics
PGx
tyrosine kinase inhibitors
TKI
bibliometric analysis
Online Access:https://www.mdpi.com/1999-4923/16/2/167

Internet

https://www.mdpi.com/1999-4923/16/2/167

Similar Items